Analyst Price Targets — STRO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 11, 2026 11:38 am | — | Truist Financial | $50.00 | $26.09 | TheFly | Sutro Biopharma assumed with a Buy at Truist |
| May 28, 2026 7:36 am | Lukas Shumway | Barclays | $56.00 | $29.69 | StreetInsider | Barclays Starts Sutro Biopharma (STRO) at Overweight |
| May 15, 2026 10:33 am | — | Wedbush | $60.00 | $38.42 | TheFly | Sutro Biopharma upgraded to Outperform from Neutral at Wedbush |
| May 15, 2026 10:16 am | Andrew Fein | H.C. Wainwright | $50.00 | $38.42 | TheFly | Sutro Biopharma price target raised to $50 from $28 at H.C. Wainwright |
| May 15, 2026 10:05 am | — | Leerink Partners | $43.00 | $38.42 | TheFly | Sutro Biopharma price target raised to $43 from $38 at Leerink |
| April 30, 2026 9:14 am | — | Mizuho Securities | $50.00 | $35.39 | TheFly | Sutro Biopharma initiated with an Outperform at Mizuho |
| March 14, 2025 1:19 pm | — | Piper Sandler | $20.00 | $8.10 | TheFly | Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler |
| October 11, 2024 7:01 am | Tazeen Ahmad | Bank of America Securities | $120.00 | $36.05 | StreetInsider | BofA Securities Reiterates Buy Rating on Sutro Biopharma (STRO) |
| October 11, 2024 6:36 am | Andrew Fein | H.C. Wainwright | $120.00 | $36.10 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO) |
| August 16, 2024 6:58 am | Asthika Goonewardene | Truist Financial | $150.00 | $42.10 | StreetInsider | Sutro Biopharma (STRO) PT Lowered to $15 at Truist Securities |
Latest News for STRO
– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 – – First dual-payload iADC from Sutro's platform entered the clinic under Astellas collaboration;…
Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading session that saw all major indices except the Nasdaq end lower, with the Nasdaq closing virtually unchanged at 24,603, up 0.04%. The combination of soaring oil prices, the Federal Reserve keeping interest rates unchanged for the third straight meeting, and bogged-down... Here Are Thursday's Top Wall Street Analyst…
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro's platform for developing dual-payload…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STRO.
U.S. House Trading
No House trades found for STRO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.